N，N-双-(3,4-二甲氧基苯基乙基)-N-甲胺盐酸盐 | 89805-39-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N，N-双-(3,4-二甲氧基苯基乙基)-N-甲胺盐酸盐
• 英文名称: YS-035 hydrochloride
• 英文别名: 2-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylethanamine;hydrochloride
• CAS: 89805-39-0
• 化学式: C21H30ClNO4
• 分子量: 395.9
• InChiKey: GYBONEHHSUABAO-UHFFFAOYSA-N

物化性质

• 溶解度：
  DMF：1mg/mL； DMSO：5mg/mL； PBS（pH 7.2）：5 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  -0.98
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  41.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Treatment of neurodegenerative disease
  申请人：——

  公开号：US20030060487A1

  公开（公告）日：2003-03-27

  In some aspects, the invention relates to treatments for peptide aggregation associated with disease states such as neurodegenerative disease, particularly physiology associated with Alzheimer's Disease, and non-neurodegenerative disease aggregation. Other aspects of the invention provide a variety of novel assays for screening candidate drugs. Yet other aspects of the present invention provide a series of compositions useful for treatment of peptide aggregation associated with disease states such as neurodegenerative disease, as determined from these assays. These compositions can be packaged in kits. Other aspects of the invention relate to the use of these compositions for the treatment and/or prevention of patients susceptible to or exhibiting symptoms characteristic of fibril formation or aberrant protein aggregation.

  在某些方面，本发明涉及与神经退行性疾病（尤其是与阿尔茨海默氏症相关的生理学疾病）等疾病状态有关的肽聚集以及非神经退行性疾病聚集的治疗方法。本发明的其他方面提供了多种用于筛选候选药物的新型检测方法。本发明的其他方面还提供了一系列用于治疗与神经退行性疾病等疾病状态相关的肽聚集的组合物，这些组合物是通过这些检测方法确定的。这些组合物可以包装成试剂盒。本发明的其他方面涉及使用这些组合物治疗和/或预防易患或表现出纤维形成或异常蛋白聚集特征症状的患者。
• TREATMENT OF NEURODEGENERATIVE DISEASE
  申请人：Minerva Biotechnologies Corporation

  公开号：EP1328261A2

  公开（公告）日：2003-07-23
• [EN] TREATMENT OF NEURODEGENERATIVE DISEASE<br/>[FR] TRAITEMENT DES MALADIES NEURODEGENERATIVES
  申请人：MINERVA BIOTECHNOLOGIES CORP

  公开号：WO2001078709A2

  公开（公告）日：2001-10-25

  In some aspects, the invention relates to treatments for peptide aggregation associated with disease states such as neurodegenerative disease, particularly physiology associated with Alzheimer's Disease, and non-neurodegenerative disease aggregation. Other aspects of the invention also provides a variety of novel assays for screening candidate drugs. Yet another aspects of the present invention also provides a series of compositions useful for treatment of neurological disease as determined from these assays. These compositions can be packaged in kits. Other aspects of the invention also relate to the use of these compositions for the treatment and/or prevention of patients susceptible to or exhibiting of a disease characteristic of fibril formation or aberrant protein aggregation.